

S3 Table. Logistic regression analysis for the DLC

	OR	95% CI	p-value
Age at RT (yr), incremental	1.01	0.98-1.04	0.552
Sex			
Female	1.00		
Male	1.06	0.45-2.50	0.893
ECOG at RT, incremental	0.37	0.19-0.74	0.005
BED ₁₀ (Gy)			
≤ 50	1.00		
> 50	1.46	0.61-3.52	0.397
Completion of RT			
No	1.00		
Yes	6.39	0.71-57.14	0.097
Extracranial disease at RT			
No	1.00		
Yes	0.37	0.13-1.06	0.063
Aging signature			
No altered	1.00		
Altered	0.82	0.33-2.01	0.662
APOBEC signature			
No altered	1.00		
Altered	1.00	N/A	
Smoking signature			
No altered	1.00		
Altered	2.73	1.09-6.81	0.031
BRCA1/2 signature			
No altered	1.00		
Altered	1.00	N/A	
MMR signature			
No altered	1.00		
Altered	0.43	0.16-1.13	0.086
UV signature			
No altered	1.00		
Altered	1.00	N/A	
POLE signature			
No altered	1.00		
Altered	0.56	0.09-3.55	0.541
TMZ signature			
No altered	1.00		
Altered	2.73	0.27-27.29	0.393
NRF pathway			
No altered	1.00		

Altered	0.59	0.24-1.48	0.206
DNA repair pathway			
No altered	1.00		
Altered	2.83	1.13-7.04	0.026
AR pathway			
No altered	1.00		
Altered	1.95	0.61-6.25	0.236
RTK-RAS pathway			
No altered	1.00		
Altered	1.17	0.35-3.96	0.799
TP53 pathway			
No altered	1.00		
Altered	0.79	0.28-2.21	0.658
Cell cycle			
No altered	1.00		
Altered	0.96	0.41-2.25	0.921
NOTCH pathway			
No altered	1.00		
Altered	1.19	0.44-3.24	0.728

AR, androgen receptor; BED₁₀, biologically effective dose with a/b=10; CI, confidence interval; DLC, durable local control group; ECOG, Eastern Cooperative Oncology Group performance status; MMR, mismatch repair; N/A, not available; OR, odds ratio; RT, radiation therapy; TMZ, temozolomide; UV, ultraviolet.